Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

被引：0

作者：

Davide Melisi

Rocio Garcia-Carbonero

Teresa Macarulla

Denis Pezet

Gael Deplanque

Martin Fuchs

Jorg Trojan

Helmut Oettle

Mark Kozloff

Ann Cleverly

Claire Smith

Shawn T. Estrem

Ivelina Gueorguieva

Michael M. F. Lahn

Al Blunt

Karim A. Benhadji

Josep Tabernero

机构：

[1] University of Verona,Oncology Department

[2] Piazzale Ludovico Antonio Scuro,undefined

[3] Hospital Universitario 12 de Octubre,undefined

[4] Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12),undefined

[5] UCM,undefined

[6] CNIO,undefined

[7] CIBERONC,undefined

[8] Vall d’Hebron University Hospital Institute of Oncology (VHIO),undefined

[9] CIBERONC,undefined

[10] C/ Natzaret,undefined

[11] 115-117,undefined

[12] Centre Hospitalier Universitaire,undefined

[13] Hôpital Riviera-Chablais,undefined

[14] Klinikum Bogenhausen,undefined

[15] Städtisches Klinikum München GmbH,undefined

[16] Goethe University Medical Center,undefined

[17] Onkologische und Hämatologische Schwerpunktpraxis,undefined

[18] Ingalls Memorial Hospital,undefined

[19] Eli Lilly and Company,undefined

[20] Erl Wood Manor,undefined

[21] Windlesham,undefined

[22] formerly of Eli Lilly and Company,undefined

[23] Eli Lilly and Company,undefined

[24] Lilly Corporate Center,undefined

[25] 6820 Wisconsin Ave.,undefined

[26] #8008,undefined

[27] Advaxis,undefined

[28] Inc.,undefined

[29] Eli Lilly and Company,undefined

[30] Vall d’Hebron University Hospital and Institute of Oncology (VHIO),undefined

[31] CIBERONC,undefined

[32] Universitat Autònoma de Barcelona,undefined

[33] P. Vall d’Hebron 119-129,undefined

来源：

British Journal of Cancer | 2018年 / 119卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1208 / 1214

页数：6

共 28 条

[1] Melisi D(2014)Pancreatic cancer: systemic combination therapies for a heterogeneous disease Curr. Pharm. Des. 20 6660-6669
[2] Calvetti L(2016)Cancer statistics, 2016 CA Cancer J. Clin. 66 7-30
[3] Frizziero M(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res. 74 2913-2921
[4] Tortora G(2015)Metastatic pancreatic cancer: is there a light at the end of the tunnel? World J. Gastroenterol. 21 4788-4801
[5] Siegel RL(2013)Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy Front. Pharmacol. 4 56-230
[6] Miller KD(2008)TGFbeta in cancer Cell 134 215-52
[7] Jemal A(2016)Genomic analyses identify molecular subtypes of pancreatic cancer Nature 531 47-840
[8] Rahib L(2008)LY2109761, a novel transforming growth factor-beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol. Cancer Ther. 7 829-4499
[9] Vaccaro V(2015)Clinical development of galunisertib (LY2157299 monohydrate), a small-molecule inhibitor of transforming growth factor-beta signaling pathway Drug Des. Devel Ther. 9 4479-2413
[10] Tamburrino A(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 2403-1825

← 1 2 3 →